Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Novel Insulin Lispro Formulation in T2DM
NCT02623465Phase 1Withdrawn
- Sponsor
- Eli Lilly and Company
- Start
- Jan 2018
- Primary completion
- Apr 2018
- Modality
- Recombinant Proteins and Enzymes
01
Overview
Phase 1, randomised, double-blind trial of insulin lispro in type 2 diabetes mellitus (T2DM) (4 arms), sponsored by Eli Lilly and Company. Primary endpoints: Area Under the Concentration Curve of Insulin Lispro and Area Under the Concentration Curve of Insulin Lispro Glucose Following a Mixed Meal. Planned start Jan 2018; status: withdrawn.
02
Drugs
insulin lispro
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT02623465.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02623465.